Duvelisib
Neoplasm Of Mature T-Cells Or NK-Cells
Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Neoplasm Of Mature T-Cells Or NK-Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Copanlisib Chonnam National University Hospital | Phase 1/2 | CCC |
Nelfinavir Swiss Cancer Institute | Phase 1 | CC |
Bortezomib Swiss Cancer Institute | Phase 1 | CC |
Cyclophosphamide National Cancer Institute (NCI) | Phase 1 | CC |
Fludarabine National Cancer Institute (NCI) | Phase 1 | CC |
Autologous Ccr4 Car T Cells National Cancer Institute (NCI) | Phase 1 | CC |
Ruxolitinib Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Same molecule, other indications
Duvelisib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →